1-[4-(Pyrid-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-bis[N-(N-methoxycarbonyl-(L)-tert-leucyl)amino]-6-phenyl-2-azahexane hydrochloride salt | 198904-39-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-[4-(Pyrid-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-bis[N-(N-methoxycarbonyl-(L)-tert-leucyl)amino]-6-phenyl-2-azahexane hydrochloride salt
• 英文别名: methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate;hydrochloride
• CAS: 198904-39-1
• 化学式: C₃₈H₅₂N₆O₇*ClH
• 分子量: 741.328
• InChiKey: LXODTZLKCNVEIG-QVFAWCHISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.63
• 重原子数：
  52
• 可旋转键数：
  18
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  171
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• Process for Preparing Atazanavir Sulphate
  申请人：CIPLA LIMITED

  公开号：US20160002166A1

  公开（公告）日：2016-01-07

  The present invention relates to a process for the preparation of Compound (A): wherein the process comprises contacting atazanavir base (Compound (II)) with sulphuric acid in a combination of two or more solvents and isolating compound (A). The present invention also relates to substantially pure Compound (A), and to Compound (A) devoid of mesityl oxide impurity. Mesityl oxide has the following formula:

  本发明涉及一种制备化合物(A)的过程：其中该过程包括将阿扎那韦碱（化合物（II））与硫酸在两种或多种溶剂的组合中接触，并分离化合物（A）。本发明还涉及基本纯净的化合物（A）以及不含二甲基苯酮杂质的化合物（A）。二甲基苯酮的化学式为：
• Protease Inhibitors
  申请人：Riggs-Sauthier Jennifer

  公开号：US20120108501A1

  公开（公告）日：2012-05-03

  The invention relates to (among other things) protease inhibitors containing both a water-soluble, non-peptidic oligomer and a lipophilic moiety-containing residue. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over protease inhibitor compounds lacking the water-soluble, non-peptidic oligomer and a lipophilic moiety-containing residue.

  本发明涉及含有水溶性非肽寡聚体和含有亲脂性基团残基的蛋白酶抑制剂（除其他外）。本发明的化合物在通过多种给药途径任何一种给予时，比缺乏水溶性非肽寡聚体和含有亲脂性基团残基的蛋白酶抑制剂化合物具有优点。
• PROCESS FOR THE PREPARATION OF ATAZANAVIR BISULFATE
  申请人：Laurus Labs Private Limited

  公开号：US20150183742A1

  公开（公告）日：2015-07-02

  The present invention relates to an improved process for the preparation of Atazanavir bisulfate Form A. The present invention also relates to a pharmaceutical composition using the Atazanavir bisulfate Form A of the invention.

  本发明涉及一种改进的制备阿扎那韦双硫酸盐A型的方法。本发明还涉及使用本发明的阿扎那韦双硫酸盐A型的制药组合物。
• PROCESS FOR PREPARING ATAZANAVIR SULPHATE
  申请人：Cipla Limited

  公开号：EP2956439B1

  公开（公告）日：2019-01-09
• COVALENT CONJUGATES COMPRISING A PROTEASE INHIBITOR, A WATER-SOLUBLE, NON-PEPTIDIC OLIGOMER AND A LIPOPHILIC MOIETY
  申请人：Nektar Therapeutics

  公开号：EP2440249A2

  公开（公告）日：2012-04-18